Biodesix released data at ASCO-SITC on a new assay that measures PD-L1 in the blood of cancer patients.
Biodesix will present data on blood-based diagnostic testing for PD-L1 at ASCO-SITC 2017; ddPCR test measuring mRNA expression from immune and cancer cells
Biodesix's GeneStrat liquid biopsy test now includes ROS1 and RET mutations. The test helps physicians make treatment decisions for cancer patients.
Clin-TOF successfully integrated into VeriStrat® workflow
Biodesix and Bioyong announced a $38M deal for development and commercialization of VeriStrat in China.
Biodesix presents data at the World Lung Conference showing the ability to stratify lung cancer patients treated with immunotherapy
Biodesix won the BizIQ award, 2016 Innovative Company of the Year.
The study results indicate that the tests have the potential to offer clinically relevant information that could help physicians selecting immunotherapies for their patients make the best decision
Biodesix, in partnership with BioRad and Qiagen, presents data from new studies at AMP.
Biodesix will present data from three studies at SITC's annual meeting.